Porth Ymchwil

Dabigatran etexilate versus warfarin in management of non-valvular atrial fibrillation in UK context: quantitative benefit-harm and economic analyses

Allbwn ymchwil: Cyfraniad at gyfnodolyn › Erthygl › adolygiad gan gymheiriaid

StandardStandard

Dabigatran etexilate versus warfarin in management of non-valvular atrial fibrillation in UK context: quantitative benefit-harm and economic analyses. / Hughes, D.; Pink, J.; Lane, S. et al.
Yn: British Medical Journal, Cyfrol 343, 31.10.2011, t. 1-14.

Allbwn ymchwil: Cyfraniad at gyfnodolyn › Erthygl › adolygiad gan gymheiriaid

HarvardHarvard

Hughes, D, Pink, J, Lane, S, Pirmohamed, M & Hughes D.A., NV 2011, 'Dabigatran etexilate versus warfarin in management of non-valvular atrial fibrillation in UK context: quantitative benefit-harm and economic analyses', British Medical Journal, cyfrol. 343, tt. 1-14. https://doi.org/10.1136/bmj.d6333

APA

Hughes, D., Pink, J., Lane, S., Pirmohamed, M., & Hughes D.A., N. V. (2011). Dabigatran etexilate versus warfarin in management of non-valvular atrial fibrillation in UK context: quantitative benefit-harm and economic analyses. British Medical Journal, 343, 1-14. https://doi.org/10.1136/bmj.d6333

CBE

Hughes D, Pink J, Lane S, Pirmohamed M, Hughes D.A. NV. 2011. Dabigatran etexilate versus warfarin in management of non-valvular atrial fibrillation in UK context: quantitative benefit-harm and economic analyses. British Medical Journal. 343:1-14. https://doi.org/10.1136/bmj.d6333

MLA

Hughes, D. et al. "Dabigatran etexilate versus warfarin in management of non-valvular atrial fibrillation in UK context: quantitative benefit-harm and economic analyses". British Medical Journal. 2011, 343. 1-14. https://doi.org/10.1136/bmj.d6333

VancouverVancouver

Hughes D, Pink J, Lane S, Pirmohamed M, Hughes D.A. NV. Dabigatran etexilate versus warfarin in management of non-valvular atrial fibrillation in UK context: quantitative benefit-harm and economic analyses. British Medical Journal. 2011 Hyd 31;343:1-14. doi: 10.1136/bmj.d6333

Author

Hughes, D. ; Pink, J. ; Lane, S. et al. / Dabigatran etexilate versus warfarin in management of non-valvular atrial fibrillation in UK context: quantitative benefit-harm and economic analyses. Yn: British Medical Journal. 2011 ; Cyfrol 343. tt. 1-14.

RIS

TY - JOUR

T1 - Dabigatran etexilate versus warfarin in management of non-valvular atrial fibrillation in UK context: quantitative benefit-harm and economic analyses

AU - Hughes, D.

AU - Pink, J.

AU - Lane, S.

AU - Pirmohamed, M.

AU - Hughes D.A., [No Value]

PY - 2011/10/31

Y1 - 2011/10/31

U2 - 10.1136/bmj.d6333

DO - 10.1136/bmj.d6333

M3 - Article

VL - 343

SP - 1

EP - 14

JO - British Medical Journal

JF - British Medical Journal

SN - 0959-535X

ER -